Nexstim
8,14
EUR
+0,25 %
5.426 følger denne virksomhed
NXTMH
First North Finland
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
+0,25%
-8,54%
+3,04%
-2,63%
+98,54%
+270%
+55,34%
+834,09%
-98,66%
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Læs mereMarkedsværdi
58,3 mio. EUR
Aktieomsætning
15,37 t EUR
P/E (adj.) (25e)
17
EV/EBIT (adj.) (25e)
18,16
P/B (25e)
10,81
EV/S (25e)
3,94
Udbytteafkast, % (25e)
-
Omsætning og EBIT-margin
Omsætning mio.
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
27.3
2025
Generalforsamling '25
15.8
2025
Delårsrapport Q2'25
Risiko
Business risk
Valuation risk
Lav
Høj
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Nexstim Plc: Invitation to the Annual General Meeting
Nexstim Plc Publishes 2024 Annual Report
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Nexstim: Returning to the buy side after a share price decline
Nexstim Plc: Managers’ Transactions, Weckroth
Nexstim Plc: Managers’ Transactions, Weckroth
Nexstim H2'24: Solid growth in line with expectations
NEXSTIM PLC’S FINANCIAL STATEMENTS BULLETIN 2024
